IrelandIreland

Shire’s icatibant set to met endpoint in hereditary angioedema

02.12.2010

Dublin – Shire plc is set to reach the primary endpoint in its largest and pivotal Phase III trial for FDA approval with its bradykinin B2 receptor antagonist bradykinin FIRAZYR® (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). According to the company, patients under icatibant treatment experienced a significantly faster time to onset of symptom relief from individual and combined cutaneous and abdominal HAE symptoms, compared to those receiving placebo. The median time to onset of symptom relief for icatibant by this measure was 2.0 hours, compared with 19.8 hours for placebo. Additionally the drug, originally developed by German Jerini AG, provided a significantly shorter time to onset of symptom relief of the patient’s primary (main) symptom. This secondary efficacy endpoint was measured by a 30% reduction in symptom score. The median time to onset of relief for FIRAZYR by this measure was 1.5 hours, compared with 18.5 hours for placebo. The results for both of these endpoints were highly statistically significant (p<0.001). Consistent with previous studies, FIRAZYR was generally well tolerated.

IrelandIreland

21.09.2011

Palo Alto/Dublin - Jazz Pharmaceuticals Inc. has bought Azur Pharma Limited in an all-stock deal that will create a specialty pharmaceutical company incorporated in Ireland. Shareholders of Jazz will own nearly 80 percent of the...

IrelandIreland

26.05.2011

Dublin – Ireland’s Elan Corporation plc has paid US$50m to access Proteostasis Therapeutics’ pipeline of proteostasis regulators, peptidomimetic compounds that regulate protein folding, protein aggregation and protein degradation...

IrelandIreland

06.02.2011

Dublin – Irish drug maker Elan Corp. plc announced it has reduced its headcount by 130 (10%) to about 1,200. Elan said a nearly half of the 130 cuts came from the firm’s R&D department, and primarily occurred at its site in San...

IrelandIreland

07.09.2010

Nottingham/Dublin – Irish researchers have identified a new target in S.aureus bacteria that cause progressive bone destruction. According to Tania Claro from Royal College of Surgeons, S. aureus makes use of its surface protein...

IrelandIreland

11.08.2010

Elan Corporation plans to advance ELND005 into phase III testing, despite data indicating that it missed the co-primary endpoints in a phase II AD201 trial for Alzheimer's. According to the trial results, ELND005, a small...

IrelandIreland

03.08.2010

Dublin/St. Paul – Irish researchers have reported that a specific gene variant may increase the severity of multiple sclerosis (MS) symptoms. For the study, which was published in Neurology (3rd August), the research team led by...

IrelandIreland

20.04.2010

Dublin – Irish neuroscience specialist Elan Corporation plc has announced it is investigating the option of spinning out its Elan Drug Technologies business, creating two publicly listed enterprises. Elan is currently assessing...

IrelandIreland

02.03.2010

Dublin – The Elan Corporation has established a novel biomarker, 11C-PiB PET, that can detect whether Alzheimer drug candidates can reduce pathogenic beta-amyloid plaques in the brains of patients. With the new marker, Elan...

IrelandIreland

17.12.2009

Dublin – Irish company Elan Corporation plc and its partner Transition Therapeutics have withdrawn patients from two ongoing phase II trials with the compound ELDN005 following the death of nine patients. The studies were stopped...

Displaying results 11 to 20 out of 49

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/1/article/shires-icatibant-set-to-met-endpoint-in-hereditary-angioedema.html

Product of the week

Products

Events

All Events

Current issue

All issues